Hepatitis B Virus (HBV)

CAS No.	Product Name	Inquiry
148717-90-2	Squalamine Squalamine is a naturally derived broad-spectrum antibiotic that is predominantly derived from the livers of dogfish and other shark species. Squalamine is undergoing trials for treatment of non-small cell lung cancer (stage I/IIA) as well as general phase I pharmacokinetic studies. In 2005, the Food and Drug Administration granted squalamine Fast Track status for approval for treatment of age-related macular degeneration. However, the Genaera Corporation, the company that has done the most work with squalamine, discontinued trials for its use in treating prostate cancer and wet age-related macular degeneration in 2007. The Squalamine project was acquired by Ohr Pharmaceutical from the now liquidated Genaera, with the prospect of continuing the development of this drug to treat wet age-related macular degeneration.
1571076-15-7	(1R)-Tenofovir-amibufenamide (1R)-Tenofovir amibufenamide ((1R)-HS-10234) is the isomer of Tenofovir amibufenamide, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study.
1571076-26-0	Tenofovir amibufenamide Tenofovir amibufenamide, a prodrug of Tenofovir, is an orally active antiviral agent. It inhibits HBV and can be used in the study of chronic hepatitis B (CHB).
1572510-42-9	JNJ-632 JNJ-632 is a modulator of hepatitis B virus (HBV) capsid assembly. It induces the formation of morphologically intact viral capsids, as demonstrated by size exclusion chromatography and electron microscopy studies.
1572510-80-5	AB-423 AB-423 is an inhibitor of HBV capsid assembly, and potent inhibits HBV replication with EC50/EC90 of 0.08-0.27 μM/0.33-1.32 μM in cells.
1578153-27-1	RO6889678 RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes.
1638266-40-6	Bersacapavir Bersacapavir is an assembly modulator of hepatitis B virus capsid.
173522-96-8	Lamivudine Salicylate Lamivudine Salicylate is used in the synthesis of Lamivudine, which is a potent nucleoside reverse transcriptase inhibitor and antiviral agent used to treat chronic hepatitis B.
1951476-79-1	Fosclevudine-alafenamide Fosclevudine alafenamide (Compound EIDD-02173) is an antiviral agent with an EC50 of 1.71 μM against HBV.
198821-22-6	Merimepodib Merimepodib is orally bioavailable IMPDH inhibitor.
201341-05-1	Tenofovir Disoproxil Tenofovir dsoproxil is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.
203935-39-1	Helioxanthin derivative 5-4-2 Helioxanthin derivative 5-4-2 had potent anti-HBV activities in HepG2.2.15 cells, with the EC50s of 1 and 0.08 microM, respectively. The lamivudine-resistant HBV, L526M/M550V double mutant strain, was also sensitive to helioxanthin and 5-4-2. This class of compounds not only inhibited HBV DNA, but also decreased HBV mRNA and HBV protein expression. The EC50 of HBV DNA inhibition was consistent with the EC50 of HBV 3.5 Kb transcript inhibition, which was 1 and 0.09 microM for helioxanthin and 5-4-2 respectively.
20547-45-9	Paederoside antiphlogosis
2072057-17-9	RG7834 RG7834 is a highly selective and orally bioavailable HBV inhibitor, suppressing HBV antigens (both HBsAg and HBeAg) and virion production.
2090064-66-5	Vebicorvir Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC50s from 1.84 μM to 7.3 μM.
211364-06-6	AT-130 AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells.
2133017-36-2	GLP-26 GLP-26 is an HBV capsid assembly modulator (CAM) that inhibits HBV DNA replication (IC50 = 3 nM) in Hep AD38 system and reduces cccDNA by >90% at 1 μM. GLP-26 disrupts pregenomic RNA encapsulation, leading to nucleocapsid disintegration and reduced cccDNA pools.
2137847-19-7	Canocapavir Canocapavir (ZM-H1505R) has orally antiviral activity. Canocapavir is a HBV capsid inhibitor that can be used in the research of Chronic hepatitis B.
2161364-69-6	HBV-IN-25 HBV-IN-25 is a good potency, orally active novel HBV cccDNA reducer. HBV-IN-25 has anti-HBeAg potency and anti-HBV activity with IC50 values of 0.58 μM and 1.15 μM, respectively. HBV-IN-25 has good aqueous solubility (LYSA(cid:0)452 μg/mL) and good PK property with no cellular toxicity.
2170998-69-1	HBV-IN-9 HBV-IN-9, a potent HBsAg (HBV Surface antigen) inhibitor (IC50 = 10 nM), is an HBV DNA production inhibitor with an IC50 of 0.15 nM in HepG2.2.15 cells. (Extracted from patent WO2018001952A1, example 20)

※ Please kindly note that our services are for research use only.